Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Lilly, which has its headquarters in Indianapolis, first announced that it would be seeking approval from Limerick City and ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion, or $3.06 a share, up ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).